Posted by Michael Wonder on 14 Nov 2023
Ipsen and Medison Pharma announce Health Canada approval of Bylvay (odevixibat) for the treatment of pruritus due to progressive familial intrahepatic cholestasis
13 November 2023 - Bylvay (odevixibat) is the first and only oral treatment available in Canada for the treatment of pruritus due to this rare genetic condition.
Today, Ipsen and Medison Pharma are pleased to announce the Health Canada approval for Bylvay (odevixibat) for the treatment of pruritus in patients aged 6 months or older with progressive familial intrahepatic cholestasis, a progressive and life-threatening liver disease.
